SCHEMBL19084681

SCHEMBL19084681

CC(C)(C)c1nn2c(=O)cc(-c3cccc(C#N)c3)[nH]c2c1-c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 4/20 0.51
ARF6 P62330 6/20 0.48
PLAT P00750 1/20 0.38
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
TRPA1 O75762 1/20 0.36
PDE4D Q08499 1/20 0.35
PDE7A Q13946 1/20 0.35
PDE3A Q14432 1/20 0.35
IDO1 P14902 1/20 0.34
NPY5R Q15761 1/20 0.34
XDH P47989 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084604 0.83 PSD (0.52) PSDARF6PLATKMT2AKDM4E
SCHEMBL19084516 0.83 PSD (0.51) PSDARF6PLAT
SCHEMBL19084663 0.83 PSD (0.52) PSDARF6PDE4DPDE7APDE3A
SCHEMBL19084615 0.82 PSD (0.52) PSDARF6PLATPDE4DPDE7A
SCHEMBL19084514 0.82 PSD (0.51) PSDARF6PLATLMNAHTT
SCHEMBL19084515 0.81 PSD (0.49) PSDARF6PLATNPY5RGAA
SCHEMBL17298733 0.80 ARF6 (0.63) PSDARF6PLATLMNAHTT
SCHEMBL19084690 0.77 PSD (0.49) PSDARF6PLATLMNAMAPT
SCHEMBL19084616 0.75 PSD (0.52) PSDARF6PLAT
SCHEMBL19084679 0.75 PSD (0.52) PSDARF6PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885PLAT 3989/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885PLAT 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.